MA43764A - Inhibiteur monovalent de l'interaction hutnfr1 - Google Patents

Inhibiteur monovalent de l'interaction hutnfr1

Info

Publication number
MA43764A
MA43764A MA043764A MA43764A MA43764A MA 43764 A MA43764 A MA 43764A MA 043764 A MA043764 A MA 043764A MA 43764 A MA43764 A MA 43764A MA 43764 A MA43764 A MA 43764A
Authority
MA
Morocco
Prior art keywords
hutnfr1
interaction
monovalent
monovalent inhibitor
inhibitor
Prior art date
Application number
MA043764A
Other languages
English (en)
Inventor
Andreas Herrmann
Roland Kontermann
Klaus Pfizenmaier
Fabian Richter
Peter Scheurich
Kirstin Zettlitz
Original Assignee
Baliopharm Ag
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baliopharm Ag, Univ Stuttgart filed Critical Baliopharm Ag
Publication of MA43764A publication Critical patent/MA43764A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
MA043764A 2016-04-05 2017-04-04 Inhibiteur monovalent de l'interaction hutnfr1 MA43764A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16163822 2016-04-05

Publications (1)

Publication Number Publication Date
MA43764A true MA43764A (fr) 2021-06-02

Family

ID=55661321

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043764A MA43764A (fr) 2016-04-05 2017-04-04 Inhibiteur monovalent de l'interaction hutnfr1

Country Status (15)

Country Link
US (1) US10689452B2 (fr)
EP (1) EP3440110B1 (fr)
JP (1) JP6784775B2 (fr)
KR (1) KR102229083B1 (fr)
CN (1) CN109641958B (fr)
AU (1) AU2017245612B2 (fr)
BR (1) BR112018070452A2 (fr)
CA (1) CA3019692A1 (fr)
EA (1) EA201892244A1 (fr)
ES (1) ES2911442T3 (fr)
IL (1) IL262111B2 (fr)
MA (1) MA43764A (fr)
MX (1) MX2018012061A (fr)
SG (1) SG11201808680RA (fr)
WO (1) WO2017174586A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091182A1 (ru) 2017-11-27 2020-07-29 Балиофарм Аг АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА
EP3810095A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
US12472266B2 (en) 2019-02-21 2025-11-18 Enosi Therapeutics Corporation Antibodies and enonomers
WO2025049818A1 (fr) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Antagonistes tnfr1 dépourvus d'activité agoniste et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
ATE514714T1 (de) * 2007-03-19 2011-07-15 Univ Stuttgart Hutnfr1-selektive antagonisten
PE20121564A1 (es) * 2009-10-27 2012-11-29 Glaxo Group Ltd Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
CN103249742B (zh) * 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体

Also Published As

Publication number Publication date
WO2017174586A1 (fr) 2017-10-12
JP2019516354A (ja) 2019-06-20
KR20190003947A (ko) 2019-01-10
IL262111A (en) 2018-11-29
IL262111B2 (en) 2023-08-01
EA201892244A1 (ru) 2019-04-30
CN109641958A (zh) 2019-04-16
MX2018012061A (es) 2019-12-16
EP3440110B1 (fr) 2022-01-26
CN109641958B (zh) 2023-10-31
CA3019692A1 (fr) 2017-10-12
AU2017245612A1 (en) 2018-10-11
US20190144555A1 (en) 2019-05-16
JP6784775B2 (ja) 2020-11-11
BR112018070452A2 (pt) 2019-02-05
ES2911442T3 (es) 2022-05-19
KR102229083B1 (ko) 2021-03-18
US10689452B2 (en) 2020-06-23
IL262111B1 (en) 2023-04-01
EP3440110A1 (fr) 2019-02-13
AU2017245612B2 (en) 2020-08-27
SG11201808680RA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MA46180A (fr) Analogues de l'amyline
EP3430731A4 (fr) Architecture d'iugw
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3325963A4 (fr) Amélioration de l'estimation de globules
EP3353328A4 (fr) Modulateurs de l'expression de kras
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3443293A4 (fr) Capteurs d'effort
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
MA49006A (fr) Inhibiteurs d'ip6k
MA46717A (fr) Variantes de l'endonucléase homing tcra
EP3378606A4 (fr) Combinaison d'assistance
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
EP3397288A4 (fr) Méthodes pour diminuer l'expression de l'ataxine-2
EP3482698A4 (fr) Instrument d'hémostase
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
EP3431808A4 (fr) Butée d'arrêt
EP3525479A4 (fr) Casque d'écoute
EP3496882A4 (fr) Plaque d'amortissement
EP3444345A4 (fr) Dérivé d'arnmicro-143
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine